ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PRAZIVETIN 500 mg/g premix for medicated feeding stuff for gilthead sea bream

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each g contains:

Active substance:
Praziquantel 500 mg

Excipients:

Qualitative composition of excipients and other constituents
Magnesium stearate
Maize starch

White or almost white powder.

3. CLINICAL INFORMATION

In accordance with Regulation 2019/4, the medicated feed label must include in a simple, clear and easily understandable manner all the clinical information listed in sections 3.1 to 3.12 (except 3.11).

3.1 Target species

Gilthead sea bream (*Sparus aurata*)

3.2 Indications for use for each target species

For the treatment of ectoparasitic infestations of the gills caused by the monogenean *Sparicotyle chrysophrii.*

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

Incorporation of the premix in feed pellets of inappropriate sizes may lead to reduced intake and therefore reduced efficacy (see section 3.9 “Administration routes and dosage”).

Unnecessary use of antiparasitics or use deviating from the instructions given in the summary of product characteristics (SPC) may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the veterinary medicinal product should be based on confirmation of the parasitic species and burden.

Use with concomitant good husbandry measures such as net changing.

3.5 Special precautions for use

Special precautions for safe use in the target species:
Palatability is reduced at higher doses than recommended and caution should be exercised not to reduce medicated feed intake. Monitor fish daily during treatment to ensure treated pellets are consumed.

Special precautions to be taken by the persons involved in the preparation/manufacturing/handling of the medicated feed or administering the medicated feed to animals:

- Dust contact with the skin and eyes can lead to irritation. Inhalation of dust can cause irritation of the upper respiratory tract.
- Avoid contact with eyes and skin. Limit dust formation. Use only with adequate ventilation.
- Personal protective equipment consisting of overalls, safety glasses, and impervious gloves and an appropriate dust mask (e.g. a disposable half-mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143) should be worn when preparing and handling the medicated feed.
- To minimise the risk of dust exposure, users administering the medicated feed to the fish in the cages under treatment should ensure that feeding is conducted in the same direction as the wind and never against it.
- In case of accidental eye contact, remove contact lenses if present and flush the eyes with plenty of clean, running water.
- In case of accidental skin contact, wash thoroughly with soap and water.
- In case of inhalation, move to fresh air.
- Should adverse effects occur, seek medical advice and show the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Gilthead sea bream (*Sparus aurata*):
None observed.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Fertility:
Do not use in breeding fish.

3.8 Interaction with other medicinal products and other forms of interaction

Do not use it with any other veterinary medicinal product.

3.9 Administration routes and dosage

In-feed use.

Dosage:
Dose regimen: 150 mg/kg bodyweight (bw)/day praziquantel for 3 consecutive days incorporated in the feed.

The 3-day treatment is recommended for maximising the chance of all the fish in the treated population to take in a uniform dose of the veterinary medicinal product and also allow for the elimination of new parasites that get attached to the fish in days 2 and 3 of the treatment.

Administration and duration of treatment:
Medicated fish feed containing the veterinary medicinal product is to be prepared only by approved feed manufacturers licensed to prepare medicated fish feeds.

Recommended method of incorporation to the feed:
The veterinary medicinal product may be incorporated by:

a) surface-coating on extruded feed pellets produced beforehand by mixing the pellets with the veterinary medicinal product with the addition of fish oil for adhesion/adsorption using appropriate drum tumbler mixing equipment.

or

b) surface-coating by mixing the veterinary medicinal product with fish oil and spraying the oily mix onto extruded feed pellets produced beforehand (under vacuum or not).

Recommended rate of incorporation of the veterinary medicinal product to the feed: 5–40 kg per ton of feed depending on feeding rate to be applied.

Recommended fish oil addition for the incorporation: 30–50 L per ton of feed.

Recommended mixing time: 10–15 minutes.

Typical composition of finished medicated diets after incorporation of the veterinary medicinal product:

Crude protein: 45–49%
Crude fats: 17–19%
Crude fibres: 1–3%
Total ash: 11–15%
Moisture: 8–10%

The incorporation rate in feed depends on the feeding rate of the fish according to fish size and water temperature. For example, for fish fed at a feeding rate of 1.5% of fish bodyweight per day, the recommended incorporation rate is 20 kg of veterinary product per ton of feed, which will yield a dose rate of 150 mg/kg biomass per day.

If different feeding rates are applied, adjust the recommended incorporation rate according to the following table.

Feeding rate of % fish bodyweight per day*	**Fish oil quantity (%) per ton of feed**	**Quantity of veterinary product (kg) per ton of medicated feed**	**Dose of praziquantel in the medicated feed (mg/kg)**	**Kg of treated fish per ton of feed per day**
0.75	4–5%	40	20,000	133,333
1.00	3–4%	30	15,000	100,000
1.25	3%	24	12,000	80,000
1.50	3%	20	10,000	66,667
1.75	3%	17.14	8,570	57,133
2.00	3%	15	7,500	50,000
2.50	3%	12.50	6,250	41,667
3.00	3%	10	5,000	33,333

*Feed the medicated feed at a reduced feeding rate such as 60–70% of that recommended by the feed manufacturer for its non-medicated feed for a particular size range of fish and seawater temperature.

For example, if the recommended feeding rate for the non medicated diet is 2.5% fish bodyweight per day, feed the medicated feed at 1.5–1.75% fish bodyweight per day. The medicated feed should be formulated in a pellet size which allows uptake also by the smaller fish in the population and reduces losses because of chewing. Use pellet size at least one size smaller than recommended by the manufacturer for its non medicated feeds for a particular size range of fish; in particular a pellet size of 2–2.5 mm is recommended for treating fish groups with an average weight between 28 and 215 g. Underdosing could result in ineffective use and may favour resistance development. To ensure a correct dosage, body weight should be determined as accurately as possible.

**Fish feeds should be representative of the feed used for the target species and fish age of the fish that are going to be treated and they should comply with EU regulations on medicated feeds including those referring to the tolerances that apply for analytical as well as active ingredient contents and with the declared specifications of the fish feed used by the manufacturer for the incorporation including its the physical characteristics (breaking resistance, sinking speed, dust content, etc.)

Further courses of treatment may be necessary, depending on the risk of re-infection and confirmation of infection. Factors such as water temperature should also be taken into account when planning treatment schedules. Studies that examined the life cycle of the parasite~~,~~ recommend that the following treatment intervals should be considered where further courses are considered necessary: 8–14 days at 26 °C, 9–21 days at 22 °C, 11–28 days at 18 °C and 14–35 days at 14 °C.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Higher doses than the recommended dosage may induce a temporary reduction in feed intake. Increased ALT/SGPT activity has been reported at five times the recommended dose, indicating possible liver toxicity.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

This veterinary medicinal product is intended to be used for the preparation of medicated feed.

The product should not be subjected to any process involving heat treatment, such as is, for example, applied during an extrusion pellet manufacturing process, because this may affect the stability of the active substance. Hence, external coating methodologies are proposed using previously prepared pellet feed and fish oil.

3.12 Withdrawal periods

120 degree days.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP52AA01

4.2 Pharmacodynamics

Praziquantel is a synthetic broad-spectrum anthelmintic, widely used in veterinary and human helminthiasis and for certain indications in captive fish.

Praziquantel works by causing severe spasms and paralysis of the worms' muscles. This paralysis is accompanied - and probably caused - by a rapid Ca^{2+} influx inside the parasite. Morphological alterations are another early effect of praziquantel. These morphological alterations are accompanied

by an increased exposure of antigens at the parasite surface. Phlatyhelminth calcium ion channels are currently the only known target of praziquantel.

There are no known reports of monogenean parasites of fish developing resistance to the active substance praziquantel; however, there are reports of suspected resistance to praziquantel developing in intestinal cestodes of Atlantic salmon following frequent field use over 1–2 decades.

4.3 Pharmacokinetics

Following oral administration, praziquantel is rapidly absorbed by the intestinal mucosa of the fish, enters the blood circulation and migrates to various body tissues including blood plasma and fish gills.

Its bioavailability in gilthead sea bream following oral administration with the feed was found to range at 49%, partially limited due to first-pass metabolism, which however is not as pronounced as in terrestrial food animals.

At the recommended oral dose of 150 mg/kg bw, the active substance reaches a C_{max} of 8.2 µg/mL in plasma at T_{max} 6 hours, while in gill tissue, the C_{max} is 39.1 µg/g at T_{max} 4 hours. Subsequently, the active substance is metabolised to a large extent within 24 h post oral dose with an elimination half-life of 14.1 h calculated in gilthead sea bream blood plasma at a water temperature of 21 °C.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 3 months.
Shelf life after incorporation in pellet feed according to directions: 3 months.

5.3 Special precautions for storage

Keep the bags tightly closed in order to protect from moisture.
This veterinary medicinal product does not require any special temperature storage conditions.

5.4 Nature and composition of immediate packaging

2 kg low density polyethylene (LDPE) bags presented in a cardboard box containing 8 bags.

20 kg low density polyethylene (LDPE) bag presented in a tri-walled paper sack with inner polyethylene (PE) lining.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines and medicated feed should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

VETHELLAS S.A.

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/25/340/001–002

8. DATE OF FIRST AUTHORISATION

23/04/2025

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARDBOARD BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PRAZIVETIN 500 mg/g premix for medicated feeding stuff

2. STATEMENT OF ACTIVE SUBSTANCES

Each g contains: Praziquantel 500 mg

3. PACKAGE SIZE

8 x 2 kg bags

4. TARGET SPECIES

Gilthead sea bream (*Sparus aurata*)

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

In-feed use.

7. WITHDRAWAL PERIODS

Withdrawal period: 120 degree days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 3 months.
Once incorporated in pellet feed according to directions, use within 3 months.

9. SPECIAL STORAGE PRECAUTIONS

Keep the bags tightly closed in order to protect from moisture.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VETHELLAS S.A.

14. MARKETING AUTHORISATION NUMBERS

EU/2/25/340/001 8 x 2 kg

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

TRI-WALLED PAPER SACK WITH INNER POLYETHYLENE (PE) LINING

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PRAZIVETIN 500 mg/g premix for medicated feeding stuff

2. STATEMENT OF ACTIVE SUBSTANCES

Each g contains: Praziquantel 500 mg

3. PACKAGE SIZE

20 kg

4. TARGET SPECIES

Gilthead sea bream *(Sparus aurata)*

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

In-feed use.

7. WITHDRAWAL PERIODS

Withdrawal period: 120 degree days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 3 months.
Once incorporated in pellet feed according to directions, use within 3 months.

9. SPECIAL STORAGE PRECAUTIONS

Keep the bags tightly closed in order to protect from moisture.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

VETHELLAS S.A.

14. MARKETING AUTHORISATION NUMBERS

EU/2/25/340/002 20 kg

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

LOW DENSITY POLYETHYLENE (LDPE) BAG (2 kg and 20 kg)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PRAZIVETIN 500 mg/g premix for medicated feeding stuff

2. STATEMENT OF ACTIVE SUBSTANCES

Each g contains: Praziquantel 500 mg

3. TARGET SPECIES

Gilthead sea bream (*Sparus aurata*)

4. ROUTES OF ADMINISTRATION

In-feed use.
Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal period: 120 degree days.

6. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 3 months.
Once incorporated in pellet feed according to directions, use within 3 months.

7. SPECIAL STORAGE PRECAUTIONS

Keep the bags tightly closed in order to protect from moisture.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

VETHELLAS S.A.

9. BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

PRAZIVETIN 500 mg/g premix for medicated feeding stuff

2. Composition

Each g contains:

Active substance:
Praziquantel 500 mg

White or almost white powder.

3. Target species

Gilthead sea bream (*Sparus aurata*)

4. Indications for use

For the treatment of ectoparasitic infestations of the gills caused by the monogenean *Sparicotyle chrysophrii.*

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Incorporation of the premix in feed pellets of inappropriate sizes may lead to reduced intake and therefore reduced efficacy (see section 3.9 “Administration routes and dosage”).

Unnecessary use of antiparasitics or use deviating from the instructions given in the summary of product characteristics (SPC) may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the veterinary medicinal product should be based on confirmation of the parasitic species and burden.

Use with concomitant good husbandry measures such as net changing.

Interaction with other medicinal products and other forms of interaction:
Do not use it with any other veterinary medicinal product.

Special precautions for safe use in the target species:
Palatability is reduced at higher doses than recommended and caution should be exercised not to reduce medicated feed intake. Monitor fish daily during treatment to ensure treated pellets are consumed.

Fertility:
Do not use in breeding fish.

Special precautions to be taken by the persons involved in the preparation/manufacturing/handling of the medicated feed or administering the medicated feed to animals:

- Dust contact with the skin and eyes can lead to irritation. Inhalation of dust can cause irritation of the upper respiratory tract.
- Avoid contact with eyes and skin. Limit dust formation. Use only with adequate ventilation.
- Personal protective equipment consisting of overalls, safety glasses, and impervious gloves and an appropriate dust mask (e.g. a disposable half-mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143) should be worn when preparing and handling the medicated feed.
- To minimise the risk of dust exposure, users administering the medicated feed to the fish in the cages under treatment should ensure that feeding is conducted in the same direction as the wind and never against it.
- In case of accidental eye contact, remove contact lenses if present and flush the eyes with plenty of clean, running water.
- In case of accidental skin contact, wash thoroughly with soap and water.
- In case of inhalation, move to fresh air.
- Should adverse effects occur, seek medical advice and show the label to the physician.

Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance:
This veterinary medicinal product is intended to be used for the preparation of medicated feed.

The product should not be subjected to any process involving heat treatment, such as is, for example, applied during an extrusion pellet manufacturing process, because this may affect the stability of the active substance. Hence, external coating methodologies are proposed using previously prepared pellet feed and fish oil.

7. Adverse events

Gilthead sea bream (*Sparus aurata*):
None observed.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}[listed in Appendix I*].

8. Dosage for each species, routes and method of administration

Dosage
Dose regimen: 150 mg/kg bodyweight (bw)/day praziquantel for 3 consecutive days incorporated in the feed.

The 3-day treatment is recommended for maximizing the chance of all the fish in the treated population to take in a uniform dose of the veterinary medicinal product and also allow for the elimination of new parasites that get attached to the fish in days 2 and 3 of the treatment.

Administration and duration of treatment
Medicated fish feed containing the veterinary medicinal product is to be prepared only by approved feed manufacturers licensed to prepare medicated fish feeds.

9. Advice on correct administration

The veterinary medicinal product may be incorporated in the feed by:

a) surface-coating on extruded feed pellets produced beforehand by mixing the pellets with the veterinary medicinal product with the addition of fish oil for adhesion/adsorption using appropriate drum tumbler mixing equipment.

or

b) surface-coating by mixing the veterinary medicinal product with fish oil and spraying the oily mix onto extruded feed pellets produced beforehand (under vacuum or not).

Recommended rate of incorporation of the veterinary medicinal product to the feed: 5–40 kg per ton of feed depending on feeding rate to be applied.

Recommended fish oil addition for the incorporation: 30–50 L per ton of feed.

Recommended mixing time: 10–15 minutes

Typical composition of finished medicated diets after incorporation of the veterinary medicinal product:

Crude protein 45–49%
Crude fats 17–19%
Crude fibres 1–3%
Total ash 11–15%
Moisture 8–10%

The incorporation rate in feed depends on the feeding rate of the fish according to fish size and water temperature. For example, for fish fed at a feeding rate of 1.5% of fish bodyweight per day the recommended incorporation rate is 20 kg of veterinary product per ton of feed, which will yield a dose rate of 150 mg/kg biomass per day.

If different feeding rates are applied, adjust the recommended incorporation rate according to the following table:

Feeding rate of % fish bodyweight per day*	**Fish oil quantity (%) per ton of feed**	**Quantity of veterinary product (kg) per ton of medicated feed**	**Dose of praziquantel in the medicated feed (mg/kg)**	**Kg of treated fish per ton of feed per day**
0.75	4–5%	40	20,000	133,333
1.00	3–4%	30	15,000	100,000
1.25	3%	24	12,000	80,000
1.50	3%	20	10,000	66,667
1.75	3%	17.14	8,570	57,133
2.00	3%	15	7,500	50,000
2.50	3%	12.50	6,250	41,667
3.00	3%	10	5,000	33,333

*Feed the medicated feed at a reduced feeding rate such as 60–70% of the recommended by the feed manufacturer for its non-medicated feed for a particular size range of fish and seawater temperature. For example, if the recommended feeding rate for the non medicated diet is 2.5% fish bodyweight per day, feed the medicated feed at 1.5–1.75% fish bodyweight per day. The medicated feed should be

formulated in a pellet size which allows uptake also by the smaller fish in the population and reduces losses because of chewing. Use pellet size at least one size smaller than recommended by the manufacturer for its non medicated feeds for a particular size range of fish; in particular a pellet size of 2–2.5 mm is recommended for treating fish groups with an average weight between 28 and 215 g. Underdosing could result in ineffective use and may favour resistance development. To ensure a correct dosage, total body weight should be determined as accurately as possible.

**Fish feeds should be representative of the feed used for the target species and fish age of the fish that are going to be treated and they should comply with EU regulations on medicated feeds including those referring to the tolerances that apply for analytical as well as active ingredient contents and with the declared specifications of the fish feed used by the manufacturer for the incorporation including its the physical characteristics (breaking resistance, sinking speed, dust content, etc.).

Further courses of treatment may be necessary, depending on the risk of re-infection and confirmation of infection. Factors such as water temperature should also be taken into account when planning treatment schedules. Studies that examined the life cycle of the parasite~~,~~ recommend that the following treatment intervals should be considered where further courses are considered necessary: 8–14 days at 26 °C, 9–21 days at 22 °C, 11–28 days at 18 °C and 14–35 days at 14 °C.

10. Withdrawal periods

120 degree days.

11. Special storage precautions

Keep out of the sight and reach of children.

Keep the bags tightly closed in order to protect from moisture.
This veterinary medicinal product does not require any special temperature storage conditions.

Shelf life after first opening the immediate packaging: 3 months.
Shelf life after incorporation in pellet feed according to directions: 3 months.

Do not use this veterinary medicinal product after the expiry date which is stated on the cardboard box, sack and bag after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines and medicated feed should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/25/340/001 2 kg low density polyethylene (LDPE) bags presented in a cardboard box containing 8 bags.

EU/2/25/340/002 20 kg low density polyethylene (LDPE) bag presented in a tri-walled paper sack with inner polyethylene (PE) lining.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder, manufacturer responsible for batch release and contact details to report suspected adverse reactions:
VETHELLAS S.A.
51, 31rst AUGOUSTOU STREET
412 21 LARISSA
GREECE
Tel.: +30 2410 551160
e-mail: info@vethellas.gr